Liraglutide

Statement by an American Association of Clinical Endocrinologists/American College of Endocrinology Consensus Panel on Type 2 Diabetes Mellitus: An Algorithm for Glycemic Control

(2013) Helena Rodbard et al.   Endocrine Practice

The once-daily human glucagon-like peptide-1 (GLP-1) analog liraglutide improves postprandial glucose levels in type 2 diabetes patients

(2011) Anne Flint et al.   ADVANCES IN THERAPY

The effect of the once-daily human glucagon-like peptide 1 analog liraglutide on the pharmacokinetics of acetaminophen

(2011) Christoph Kapitza et al.   ADVANCES IN THERAPY

Cost-effectiveness of liraglutide versus rosiglitazone, both in combination with glimepiride in treatment of type 2 diabetes in the US

(2011) W.C. Lee et al.   CURRENT MEDICAL RESEARCH AND OPINION

Glucagon-like Peptide–1 Analogues for Type 2 Diabetes Mellitus

(2011) Baptist Gallwitz   DRUGS

Mild Renal Impairment and the Efficacy and Safety of Liraglutide

(2011) Jaime A. Davidson et al.   Endocrine Practice

Tolerability, pharmacokinetics and pharmacodynamics of the once-daily human GLP-1 analog liraglutide in Japanese healthy subjects: a randomized, double-blind, placebo-controlled dose-escalation study

(2011) S. Irie et al.   INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS

One year of liraglutide treatment offers sustained and more effective glycaemic control and weight reduction compared with sitagliptin, both in combination with metformin, in patients with type 2 diabetes: a randomised, parallel-group, open-label trial

(2011) R. Pratley et al.   INTERNATIONAL JOURNAL OF CLINICAL PRACTICE

GLP-1 and Calcitonin Concentration in Humans: Lack of Evidence of Calcitonin Release from Sequential Screening in over 5000 Subjects with Type 2 Diabetes or Nondiabetic Obese Subjects Treated with the Human GLP-1 Analog, Liraglutide

(2011) Laszlo Hegedüs et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Liraglutide Treatment Is Associated with a Low Frequency and Magnitude of Antibody Formation with No Apparent Impact on Glycemic Response or Increased Frequency of Adverse Events: Results from the Liraglutide Effect and Action in Diabetes (LEAD) Trials

(2011) John B. Buse et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Glucagon-like peptide-1 analog liraglutide in combination with sulfonylurea safely improves blood glucose measures vs sulfonylurea monotherapy in Japanese patients with type 2 diabetes: Results of a 52-week, randomized, multicenter trial

(2011) Yutaka Seino et al.   Journal of Diabetes Investigation

Influence of hepatic impairment on pharmacokinetics of the human GLP-1 analogue, liraglutide

(2010) Anne Flint et al.   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

Results of a model analysis of the cost-effectiveness of liraglutide versus exenatide added to metformin, glimepiride, or both for the treatment of type 2 diabetes in the United States

(2010) Won Chan Lee et al.   CLINICAL THERAPEUTICS

Efficacy and safety of the once-daily human GLP-1 analogue, liraglutide, vs glibenclamide monotherapy in Japanese patients with type 2 diabetes

(2010) Y. Seino et al.   CURRENT MEDICAL RESEARCH AND OPINION

Switching to Once-Daily Liraglutide From Twice-Daily Exenatide Further Improves Glycemic Control in Patients With Type 2 Diabetes Using Oral Agents

(2010) J. B. Buse et al.   DIABETES CARE

Co-administration of liraglutide with insulin detemir demonstrates additive pharmacodynamic effects with no pharmacokinetic interaction

(2010) L. Morrow et al.   DIABETES OBESITY & METABOLISM

Patient-reported outcomes following treatment with the human GLP-1 analogue liraglutide or glimepiride in monotherapy: results from a randomized controlled trial in patients with type 2 diabetes

(2010) B. W. Bode et al.   DIABETES OBESITY & METABOLISM

Liraglutide provides similar glycaemic control as glimepiride (both in combination with metformin) and reduces body weight and systolic blood pressure in Asian population with type 2 diabetes from China, South Korea and India: a 16-week, randomized, doubl

(2010) W. Yang et al.   DIABETES OBESITY & METABOLISM

Liraglutide, a once-daily human glucagon-like peptide 1 analogue, provides sustained improvements in glycaemic control and weight for 2 years as monotherapy compared with glimepiride in patients with type 2 diabetes

(2010) A. Garber et al.   DIABETES OBESITY & METABOLISM

Glucagon-Like Peptide-1 Receptor Agonists Activate Rodent Thyroid C-Cells Causing Calcitonin Release and C-Cell Proliferation

(2010) Lotte Bjerre Knudsen et al.   ENDOCRINOLOGY

Population Pharmacokinetics of Liraglutide, a Once-Daily Human Glucagon-Like Peptide-1 Analog, in Healthy Volunteers and Subjects With Type 2 Diabetes, and Comparison to Twice-Daily Exenatide

(2010) Estelle Watson et al.   JOURNAL OF CLINICAL PHARMACOLOGY

Effect of Three Different Injection Sites on the Pharmacokinetics of the Once-Daily Human GLP-1 Analogue Liraglutide

(2010) Christoph Kapitza et al.   JOURNAL OF CLINICAL PHARMACOLOGY

Liraglutide versus sitagliptin for patients with type 2 diabetes who did not have adequate glycaemic control with metformin: a 26-week, randomised, parallel-group, open-label trial

(2010) Richard E Pratley et al.   LANCET

A Meta-Analysis of Placebo-Controlled Clinical Trials Assessing the Efficacy and Safety of Incretin-Based Medications in Patients with Type 2 Diabetes

(2010) Walid K.H. Fakhoury et al.   PHARMACOLOGY

Patient-reported outcomes in patients with type 2 diabetes treated with liraglutide or glimepiride, both as add-on to metformin

(2010) Kjeld Hermansen et al.   Primary Care Diabetes

Effect of renal impairment on the pharmacokinetics of the GLP-1 analogue liraglutide

(2009) Lisbeth V. Jacobsen et al.   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

Long-term outcomes in patients with type 2 diabetes receiving glimepiride combined with liraglutide or rosiglitazone

(2009) Sean D Sullivan et al.   Cardiovascular Diabetology

GLP-1R Agonist Liraglutide Activates Cytoprotective Pathways and Improves Outcomes After Experimental Myocardial Infarction in Mice

(2009) M. H. Noyan-Ashraf et al.   DIABETES

Standards of Medical Care in Diabetes--2009

(2009)   DIABETES CARE

Efficacy and Safety of the Human Glucagon-Like Peptide-1 Analog Liraglutide in Combination With Metformin and Thiazolidinedione in Patients With Type 2 Diabetes (LEAD-4 Met+TZD)

(2009) B. Zinman et al.   DIABETES CARE

Increased Risk of Acute Pancreatitis and Biliary Disease Observed in Patients With Type 2 Diabetes: A retrospective cohort study

(2009) R. A. Noel et al.   DIABETES CARE

The effects of glucagon-like peptide-1 on the beta cell

(2009) T. Vilsbøll   DIABETES OBESITY & METABOLISM

Weight loss with liraglutide, a once-daily human glucagon-like peptide-1 analogue for type 2 diabetes treatment as monotherapy or added to metformin, is primarily as a result of a reduction in fat tissue

(2009) J. Jendle et al.   DIABETES OBESITY & METABOLISM

Improved glycaemic control with minimal hypoglycaemia and no weight change with the once-daily human glucagon-like peptide-1 analogue liraglutide as add-on to sulphonylurea in Japanese patients with type 2 diabetes

(2009) K. Kaku et al.   DIABETES OBESITY & METABOLISM

Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with Type 2 diabetes (LEAD-1 SU)

(2009) M. Marre et al.   DIABETIC MEDICINE

Liraglutide vs insulin glargine and placebo in combination with metformin and sulfonylurea therapy in type 2 diabetes mellitus (LEAD-5 met+SU): a randomised controlled trial

(2009) D. Russell-Jones et al.   DIABETOLOGIA

Liraglutide

(2009) Katherine F. Croom et al.   DRUGS

Adding liraglutide to oral antidiabetic drug therapy: onset of treatment effects over time

(2009) B. Gallwitz et al.   INTERNATIONAL JOURNAL OF CLINICAL PRACTICE

Absence of QTc Prolongation in a Thorough QT Study With Subcutaneous Liraglutide, a Once-Daily Human GLP-1 Analog for Treatment of Type 2 Diabetes

(2009) Dhruba J. Chatterjee et al.   JOURNAL OF CLINICAL PHARMACOLOGY

Effects of liraglutide in the treatment of obesity: a randomised, double-blind, placebo-controlled study

(2009) Arne Astrup et al.   LANCET

Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6)

(2009) John B Buse et al.   LANCET

Effect of intensive control of glucose on cardiovascular outcomes and death in patients with diabetes mellitus: a meta-analysis of randomised controlled trials

(2009) Kausik K Ray et al.   LANCET

A Simulation of the Comparative Long-term Effectiveness of Liraglutide and Glimepiride Monotherapies in Patients with Type 2 Diabetes Mellitus

(2009) Sean D Sullivan et al.   PHARMACOTHERAPY

Adding Liraglutide to Oral Antidiabetic Drug Monotherapy: Efficacy and Weight Benefits

(2009) Michael Nauck et al.   POSTGRADUATE MEDICINE

Medical Management of Hyperglycemia in Type 2 Diabetes: A Consensus Algorithm for the Initiation and Adjustment of Therapy: A consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes

(2008) D. M. Nathan et al.   DIABETES CARE

Efficacy and Safety Comparison of Liraglutide, Glimepiride, and Placebo, All in Combination With Metformin, in Type 2 Diabetes: The LEAD (Liraglutide Effect and Action in Diabetes)-2 study

(2008) M. Nauck et al.   DIABETES CARE

Dose-dependent improvement in glycemia with once-daily liraglutide without hypoglycemia or weight gain: A double-blind, randomized, controlled trial in Japanese patients with type 2 diabetes

(2008) Y. Seino et al.   DIABETES RESEARCH AND CLINICAL PRACTICE

Beneficial effects of once-daily liraglutide, a human glucagon-like peptide-1 analogue, on cardiovascular risk biomarkers in patients with Type 2 diabetes

(2008) J.-P. Courrèges et al.   DIABETIC MEDICINE

Liraglutide, a once-daily human GLP-1 analogue, improves pancreatic B-cell function and arginine-stimulated insulin secretion during hyperglycaemia in patients with Type 2 diabetes mellitus

(2008) T. Vilsbøll et al.   DIABETIC MEDICINE

Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial

(2008) Alan Garber et al.   LANCET